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Abstracts / Urological Science 26 (2015) 294e300 297Can that save the cost with avoidance of repeated semen analysis if the
ﬁrst semen analysis had nonmotile sperm density <100,00/ml.
Materials and Methods: From Jan 2010 to Dec. 2014 a total of 419 men
underwent vasectomy for birth control in our hospital. Patients de-
mographics and postvasectomy semen analysis results were collected
retrospectively.
Results: During the period of recent 5 years, 419 patients underwent va-
sectomy in our hospital. Most of the patients has 2 or more children after
marriage. Postvasectomy semen analysis was completed within the 3-6
months after surgery. No patient has motile sperm in their PVSA. Few
patients had nonmotile sperm with the concentration <100,000/ml (AUA
clearance parameter). Repeated semen analysis conﬁrm the azospermia
later. The cost saving is not high.
Conclusion: The AUA special clearance parameter is not applied in our
hospital. The cost saving is not efﬁcacy than the compensation of legal
problem. So repeated semen analysis is still warranted in our hospital until
azospermia conﬁrmed.
MP2-6:
PEARLS, TRICKS, AND QUIRKS OF THE RECONSTRUCTION FOR
HYPOSPADIAS AND CHORDEE
Jesun Lin 1,2, Herng-Jye Jiang 1, Jian Ting Chen 1, Bai-Fu Wang 1, Chin-pao
Chang 1, Mon-I. Yen 1, Sheng-Hsien Huang 1, Hon-Jen Shi 1, Ming-Chih
Chou 2. 1Division of Urology, Department of Surgery, Changhua Christian
Hospital, Changhua, Taiwan; 2 Institute of Medicine, Chung Shan Medical
University, Taichung, Taiwan
Purpose: We reviewed our 33 years experience in the management of
hypospadias, chordee and their complications after reconstruction in order
to understand their presenting Problems. We would recommend the fac-
tors of successful techniques for this congenital disease of penis.
Materials and Methods:We reviewed the records of 998 hypospadias and
chordee patients between January 1981 and December 2014. The com-
plications after reconstruction might be single or combined with several
presenting problems in the same patient. This article represents a collec-
tion of recommendations, technical nuances, and innovative management
techniques that have been found to contribute to the success of hypo-
spadias and chordee surgery. We would classify the main problems of
complications to be (1) 89 urethrocutaneous ﬁstulae, (2) 36 urethral
strictures, (3) 15 meatal stenosis (4) 38 remaining chordee, (5) 14 diver-
ticula and (6) 6 hairy urethra. The penile shaft and perineum ﬁstulae were
repaired with the “pants-over-vest urethroplasty modiﬁed to the proce-
dure of Turner-Warwick. The coronal ﬁstulas were converted into repair
for coronal hypospadias. The remaining urethral plate was tubularized
with or without a relaxing midline incision (Reddy-Snodgrass). We
wrapped dorsal dartos or subcutaneous ﬂap to cover the neourethra for
preventing urethrocutaneous ﬁstula. The meatal stenosis was performed
with dorsal meatotomy, Y-V glans ﬂap, meatal skin graft and transverse
meatotomy. Residual chordee were performed with dorsal plication,
excision the chordee, the urethral diverticula were excised and tailored for
redo-urethroplasty. Hairy urethra were resected and then urethroplasty.
We performed double-tube stent and vacuum drain in subcutaneous layer
for prevention of bladder spasm, hematoma and infection.
Results: The over all successful rate is 85% in one stage surgery for the
fresh cases. The number of redo-operations for their presenting problems
of complications ranged from 1 to 8 attempts. The successful rate for
urethrocutaneous ﬁstula is 76%, for urethral strictures is 82%, for meatal
stenosis is 70%, for chordee is about 70%, for diverticula is about 85%, for
the hairy urethra is about 70%. We followed up the outcome of consequent
surgery from 6 months to more than ten years.
Conclusions: The successful surgery of the hypospadias, chordee redo
operation for them requires radical correction of all deformities. It is true
that“Experience is by far the best teacher. It might be said that unless the
technique and subsequent good results of an individual method are
transferable to others, the technique as taught is suspect”said by Dr. John
W. Duckett.Moderated Poster-3
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MP3-1:
ACCURACY OF MAGNETIC RESONANCE IMAGING FOR PROSTATE
CANCER: EXPERIENCE IN CHANGHUA CHRISTIAN HOSPITAL
You-Chiuan Chien, Bai-Fu Wang. Divisions of Urology, Department of
Surgery, Changhua Christian Hospital, Changhua, Taiwan
Purpose: To evaluate the accuracy of MRI acquisition for staging of pros-
tate cancer (PCa) in robot-assisted laparoscopic radical prostatectomy
(RALAP).
Materials and Methods: 33 consecutive patients underwent a multi-
parametric MRI protocol prior to RALAP. Analyses were carried out to
predict side-speciﬁc extracapsular extension using variables determined
preoperatively, including 3.0-Tesla magnetic resonance imaging ﬁndings
(T2-weighted and diffusion-weighted imaging). A prediction model was
then constructed and applied to the validation study sample.
Results: Of 33 eligible patients, histology showed ECE I in 14 (42%) cases.
MRI sensitivity and speciﬁcity to detect ECE were 40 and 86%.
Conclusions:MRI provides a high speciﬁcity and relatively low sensitivity
for local staging of prostate cancer.
MP3-2:
PURINE ANALOGUE ENERGI-F706 INDUCES APOPTOSIS OF 786-O
RENAL CARCINOMA CELLS VIA 5'-ADENOSINE MONOPHOSPHATE-
ACTIVATED PROTEIN KINASE ACTIVATION
Chao-Yu Hsu 1, Chun-Hsiang Lin 2, Shao-Hsuan Kao 2. 1Divisions of Urology,
Department of Surgery, Tungs Taichung MetroHarbor Hospital, Taichung,
Taiwan; 2 Institute of Biochemistry, Microbiology and Immunology, College
of Medicine, Chung Shan Medical University, Taichung, Taiwan
Purpose: Purine compounds are known to activate 5'-adenosine mono-
phosphate-activated protein kinase (AMPK), which has important roles in
treatments for renal cell carcinoma (RCC). The present study was aimed to
investigate the effects of the purine analogue ENERGI-F706 on the human
renal carcinoma cell line 786-O and the underlying mechanisms.
Materials and Methods: Cell viability and cell cycle distribution were
determined using the MTT assay in the absence or presence of ENERGI-
F706 and ﬂow cytometric analysis, respectively. Phosphorylation and
protein levels were assessed by immunoblot analysis. The involvement of
AMPK signaling was demonstrated using a speciﬁc inhibitor.
Results: ENERGI-F706 (0.2e0.6 mg/ml) signiﬁcantly decreased the cell
viability to up to 36.4± 2.4% of that of the control. Compared to 786-O
cells, ENERGI-F706 exerted less suppressive effects on the viability of the
human non-tumorigenic renal cell line HK-2. Flow cytometric analysis
showed that ENERGI-F706 contributed to cell cycle arrest at S-phase and
triggered apoptosis of 786-O cells. Immunoblot analysis revealed that anti-
apoptotic B-cell lymphoma 2 (Bcl-2) levels were reduced and pro-
apoptotic Bcl-2-associated X protein levels were diminished. In addition,
activation of caspase-9, caspase-3 and poly(adenosine diphosphate ribose)
polymerase (PARP) was promoted in 786-O cells in response to ENERGI-
F706. Effects of ENERGI-F706 on AMPK cascades were investigated and the
results showed that ENERGI-F706 enhanced phosphorylation of AMPKa
(T172) and p53 (S15), a downstream target of AMPK. In addition, the AMPK
activation, p53 (S15) phosphorylation, reduction of Bcl-2, cleavage of
caspase-3 and PARP aswell as suppressed cell viability induced by ENERGI-
F706 were reversed in the presence of AMPK inhibitor compound C
(dorsomorphin).
Conclusions: ENERGI-F706 signiﬁcantly suppressed the viability of 786-O
cells via induction of cell cycle arrest and apoptosis, attributing to AMPK
and p53 activation and subsequent cell cycle regulatory and apoptotic
signaling. It was therefore indicated that ENERGI-F706 may be suitable for
the treatment of RCC.
